Advanced therapies have introduced new approaches to treating diseases by using living cells, genetic material, or engineered tissues. Unlike many conventional medicines, these products may involve patient-specific materials, complex biological processes, and limited manufacturing timelines. These characteristics create unique quality and operational challenges. Good Manufacturing Practices provide a framework for controlling manufacturing activities and ensuring that products are consistently produced and handled according to established quality standards. Their application helps manufacturers identify risks, document procedures, and maintain oversight throughout the product lifecycle.
Good Manufacturing Practices are quality requirements and operational principles used to help ensure that medicinal products are manufactured and controlled consistently. For advanced therapies, GMP considerations can include biological material sourcing, processing conditions, contamination prevention, product identification, storage, and transportation.
Cell and gene therapies can be particularly sensitive to changes in temperature, handling, and processing conditions. Manufacturing procedures must therefore be designed around the characteristics of each product. For example, autologous cell therapies use cells collected from an individual patient, making accurate identification and traceability especially important. Allogeneic therapies use cells from a donor or established source and require appropriate controls for donor eligibility, material quality, and manufacturing consistency.
Important GMP elements include:
Quality management systems: Defined responsibilities, approved procedures, risk assessments, and quality reviews help maintain consistent manufacturing practices.
Personnel training: Staff must understand relevant procedures, contamination controls, documentation requirements, and product-specific handling instructions.
Facility and equipment controls: Suitable cleanrooms, environmental monitoring, equipment qualification, and maintenance help reduce contamination and process variability.
Material traceability: Raw materials, biological starting materials, reagents, and finished products require appropriate identification and records.
Documentation: Batch records and controlled procedures provide evidence of the activities performed, results obtained, and decisions made during production.
GMP requirements depend on the product, manufacturing process, development stage, and applicable jurisdiction. Manufacturers must determine which regulatory standards apply and maintain suitable controls throughout development and production.
Quality control and regulatory compliance are essential components of advanced therapy manufacturing. Because biological products may show variability, manufacturers need appropriate methods to evaluate identity, purity, potency, safety, and other relevant quality attributes. Testing strategies should reflect the product's characteristics and the risks associated with its intended use.
Quality assurance teams oversee whether manufacturing activities follow approved procedures and applicable requirements. Quality control teams conduct or manage testing to determine whether materials and products meet established specifications. Although these functions are closely connected, they serve different purposes within the overall quality system.
Key practices supporting quality and compliance include:
Process validation: Demonstrating that manufacturing processes can consistently achieve predefined outcomes, where validation is appropriate for the process and development stage.
Environmental monitoring: Assessing cleanroom conditions and potential contamination risks through suitable monitoring programs.
Contamination control: Applying appropriate cleaning, aseptic processing, personnel practices, and material handling procedures.
Deviation management: Investigating unexpected events, documenting their causes, and implementing corrective and preventive actions when necessary.
Product testing and release: Reviewing required test results, batch documentation, and quality decisions before authorizing product release.
Cold chain management: Maintaining specified storage and transportation conditions to protect product stability and integrity.
Regulatory expectations may differ across regions. In the United States, the Food and Drug Administration establishes applicable requirements for biological products and cellular and gene therapy manufacturing. In the European Union, relevant GMP guidelines and advanced therapy medicinal product requirements apply according to the product and circumstances. Manufacturers must consult current regulations and guidance relevant to their operations.
Good Manufacturing Practices are fundamental to maintaining quality throughout advanced therapy development and manufacturing. By combining effective quality systems, trained personnel, controlled facilities, reliable testing, and thorough documentation, organizations can better manage the distinctive challenges of biological products. Continuous monitoring and process improvement also help identify potential weaknesses and support compliance as manufacturing methods evolve. These practices provide an essential foundation for producing advanced therapies with appropriate controls over quality, safety, and consistency.